Leveraging Large Language Models with NetraAI for Clinical Trial De-Risking: Launching NetraGPT
NetraAI represents a distinctive, Good Clinical Practice (GCP)-authenticated machine learning architecture that offers an accessible interface for researchers to engage with consolidated multimodal datasets. This empowers sponsors to uncover explainable patient...
Hypothesis Generation Using NetraAI Reveals Genetic Drivers of Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and can be divided into three histological subtypes with distinct presentation and prognoses: adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC).1 In addition to...
Discovery of Unique Genetic Subtypes Contributing to Heterogeneity in Alzheimer’s Disease Progression Using NetraAI
Alzheimer’s disease (AD) is a neurodegenerative disease that contributes to 60-70% of all dementia cases and is characterized by neuronal cell damage and cognitive decline.1 Currently, drugs for AD target symptom control and there is no effective curative therapy for...
